Secondly, Bullseye 2 (NCT04443062), a multicenter, randomized, open-label, phase II study, investigating [177Lu]Lu-PSMA-617 in men with recurrence prostate cancer who are eligible for ADT. The gene discussed is FOLH1; the disease is prostate carcinoma.